Arvinas (NASDAQ:ARVN) Releases Earnings Results, Beats Expectations By $0.06 EPS

Arvinas (NASDAQ:ARVN) posted its quarterly earnings data on Tuesday. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.06, Zacks reports. Arvinas had a return on equity of 1.91% and a net margin of 2.94%. The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $16.93 million. During the same quarter in the previous year, the business earned ($0.48) EPS. The company’s quarterly revenue was down 98.8% compared to the same quarter last year.

Here are the key takeaways from Arvinas’ conference call:

• ARV-393 is expected to deliver initial monotherapy data at ASH in December, focused on T-cell lymphoma, with additional B-cell lymphoma, durability, and glofitamab-combination data planned for mid-2027. Management said early responses have been observed across lymphoma subtypes and views the program as potentially competitive, though most initial patients were treated below predicted efficacious exposure levels.
• The company plans to dose SBMA patients with the oral ARV-027 androgen-receptor degrader in the first half of 2027, following healthy-volunteer data. Management is targeting approximately 50% reduction in polyQ-AR, which it believes could translate into improved muscle strength and endurance based on preclinical findings.
• ARV-6723, Arvinas’ oral HPK1 degrader, has entered a Phase I monotherapy trial, with pembrolizumab combination dosing planned for the first half of 2027 and initial clinical data expected in the second half of 2027. The company highlighted preclinical activity in checkpoint-resistant models and complete tumor regressions in combination studies, but clinical validation remains pending.
• Development of the LRRK2 degrader ARV-102 remains constrained by an ongoing FDA clinical hold in the U.S.; the company now expects to initiate a Phase Ib PSP trial in Europe and the U.K. in 2027 and may add U.S. sites later. While biomarker and oculomotor findings strengthened management’s confidence, the relationship between these measures and meaningful clinical benefit is not yet established.
• Arvinas ended the quarter with $558.9 million in cash, restricted cash, and marketable securities and projects funding into the second half of 2028. Lower year-over-year R&D and G&A spending supports the runway, although the balance declined from $685.4 million at year-end 2025 and some programs may extend beyond current cash guidance.

Arvinas Stock Down 7.2%

ARVN traded down $0.54 on Tuesday, reaching $6.98. The company’s stock had a trading volume of 242,653 shares, compared to its average volume of 820,211. The stock has a 50 day moving average of $8.06 and a two-hundred day moving average of $9.68. Arvinas has a fifty-two week low of $6.74 and a fifty-two week high of $14.51. The company has a market capitalization of $450.35 million, a price-to-earnings ratio of 69.96 and a beta of 1.80.

Analysts Set New Price Targets

A number of brokerages recently commented on ARVN. BTIG Research restated a “buy” rating and set a $18.00 target price on shares of Arvinas in a report on Tuesday, August 4th. Wedbush boosted their price target on shares of Arvinas from $11.00 to $12.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Wells Fargo & Company cut shares of Arvinas from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $15.00 to $11.00 in a research report on Tuesday, August 4th. Morgan Stanley set a $10.00 price objective on shares of Arvinas in a report on Monday, August 10th. Finally, Weiss Ratings downgraded shares of Arvinas from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, October 23rd. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.40.

Arvinas Company Profile

Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines based on targeted protein degradation. The company’s proprietary PROTAC® protein degrader platform is designed to direct the body’s natural cellular machinery to selectively break down disease-causing proteins that may be difficult to address with conventional drug approaches.

Arvinas has concentrated its research and development efforts primarily on oncology, including hormone-driven cancers. Its pipeline has included vepdegestrant, an estrogen receptor protein degrader being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, as well as other investigational degraders targeting cancer-related proteins.